Accès ouvert
2026
article
OpenAlex
Jared Weiss, John Kaczmar, Ashish Chintakuntlawar, MD Francis P. Worden et autres
Importance: The incidence of human papillomavirus type 16 (HPV16-positive) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) is rising. Approved therapies offer a durable response to a minority of patients. Objective: To determine the efficacy and safety of a therapeutic HPV16-targeted …
us, gb, ie
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Sung Jun, Daniel Alvarez, Krithik Tella, Jacob Wells et autres
PURPOSE There is a heterogeneous practice pattern in prophylactic percutaneous endoscopic gastrostomy (PEG) tube placement, and it is unclear whether increased hospitalization is driven by those with versus without prophylactic PEG tube. To address this knowledge gap, we performed an observational cohort …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Jiaxiang Sun, Yusuf Sadek, Yiming Zhu, Sujith Baliga et autres
e18000 Background: Current risk stratification and adjuvant treatment decisions for head and neck cancer following surgical resection rely primarily on pathological risk factors. The growing adoption of digital pathology presents an opportunity to leverage histopathological image features to enhance risk stratification accuracy. …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Nandini Bangalore, Maximos McCune, Henry E. Wang, Mohammed Aidja et autres
e18114 Background: Anemia may be associated with worse clinical outcomes in patients with head and neck squamous cell carcinoma (HNSCC), which may be related to tumor hypoxia and decreased sensitivity to radiation therapy. However, the prognostic role of baseline hemoglobin (Hgb) is …
us
(code pays fourni par la source)
2026
article
OpenAlex
Alec Kotler, Om Desai, Kevin Agner, Jacob Wells et autres
e18099 Background: Head and neck cancer (HNC) patients often experience pain from intense radiation treatment. Opioids work well to minimize this side effect. However, persistent use during and after treatment can cause significant health problems. There is little data in the literature …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Jennifer Dorcas Hwang, Mateus Trinconi Cunha, Molly Russell, Gretchen Pardo et autres
6046 Background: ICI-containing regimens are the standard first-line therapies for R/M HNSCC. However, the optimal therapeutic regimen after progression on ICI-containing therapies remains uncertain. This study compares outcomes among patients (pts) who received either second-line cetuximab plus ICI (CICI) or cetuximab plus …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Marcelo Raul Bonomi, Jungmin Shin, Madison Sikorski, Mateus Trinconi Cunha et autres
6044 Background: Standard-dose chemotherapy combined with immunotherapy improves response rates in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), but its use is often constrained by significant toxicity. Metronomic chemotherapy (MCT) offers a potentially better-tolerated alternative while preserving immune-modulatory …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Yusuf Sadek, Jiaxiang Sun, Yiming Zhu, Sujith Baliga et autres
6022 Background: Immunohistochemistry (IHC) marker testing and identification of pathological features are essential tasks in surgical pathology following resection of head and neck cancers. However, IHC testing is time-consuming, and identifying pathologic features typically requires examination of multiple slides. We hypothesized that …
us
(code pays fourni par la source)
Accès ouvert
2026
editorial
OpenAlex
Sujith Baliga, Priyanka Bhateja
The current issue focuses on biomarkers beyond clinical staging that may be predictive of treatment outcomes in head and neck cancer. Locally advanced head and neck cancer has known predictive markers like smoking and alcohol history, virally mediated pathology and well-known genomic …
us
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Paul L. Swiecicki, Glenn J. Hanna, Jessica L. Geiger, Takao Fujisawa et autres
PURPOSE: To assess the safety and efficacy of enfortumab vedotin (EV) and pembrolizumab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). PATIENTS AND METHODS: In this open-label, multicohort, phase II study (NCT04225117), the R/M HNSCC …
us, jp
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Mateus Trinconi Cunha, Fahad Rind, Priyanka Bhateja, Esmerina Tili et autres
Abstract Background: a/mHNSCC exhibits poor prognosis and limited immunotherapy efficacy. Weekly low-dose chemotherapy may enhance immunogenicity while reducing toxicity. We conducted a phase II trial of weekly low-dose chemotherapy plus cemiplimab as first-line treatment in a/mHNSCC, with integrated genomic profiling to explore …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Chongwen Cao, Weiyi Gong, Hui Li, Bixiao Zhao et autres
Abstract Background: HPV is a major oncogenic driver of head and neck cancers (HNC). However, the epigenomic heterogeneity of the HPV genome—particularly single-cell chromatin accessibility patterns—and its relevance to cancer progression remain unclear. This study characterizes the chromatin-accessibility landscape of patient-derived HPV …
us
(code pays fourni par la source)